Evidence map›Paper›PMID 40599486›Full record

ArticleOpen forum infectious diseases2025

Insights to a Cure: Unique Controller Phenotypes in the Rotterdam HIV-2 Cohort.

Kathryn S Hensley, Rob A Gruters, Els van Nood, Mariana de Mendonça Melo, Ronald J Overmars, Alicja U Górska, Casper Rokx, Cynthia Lungu, David A M C van de Vijver, Thibault Mesplède and 1 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kathryn S HensleyDepartment of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0003-1675-2445
Rob A GrutersDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-8486-5903
Els van NoodDepartment of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-4962-4792
Mariana de Mendonça MeloDepartment of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-7315-8226
Ronald J OvermarsDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-8984-0633
Alicja U GórskaDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.
Casper RokxDepartment of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-1904-6450
Cynthia LunguDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0003-1231-9628
David A M C van de VijverDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0001-5877-8526
Thibault MesplèdeDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0003-0515-9128
Jeroen J A van KampenDepartment of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-7625-8230

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: HIV-2, although less common than HIV-1, exhibits a higher proportion of elite controllers (ECs), who can suppress HIV without antiretroviral therapy (ART), a phenomenon rarely observed in HIV-1. Studying ECs could yield insights into viral control mechanisms and potentially lead to a cure. Methods: We retrospectively characterized a cohort of people with HIV-2 who received care at the Erasmus University Medical Center, Rotterdam, Netherlands. The aim was to identify categories of ECs based on plasma viral loads, CD4+ T-cell count, and responses to ART. Results: Between 1989 and 2023, 52 people with HIV-2 were included, primarily of West African origin (80.8%). Follow-up ranged from <1 to 32 years (median, 16 years). Seven participants were lost to follow-up (13.5.%), and 18 participants died (34.6%), 7 before ART availability due to AIDS. The remaining 40 participants were included in the detailed analysis. Thirteen were ECs with CD4+ T cells >350 cells/mm Conclusions: These data highlight relevant trajectories among ECs. Understanding the underlying mechanisms can inform decisions on treatment and contribute to finding a cure for all people with HIV.

Indexed as

elite controllersHIV-2HIV-2 elite controlnonviremic progressorrecontroller

Identifiers

PMID40599486
PMCPMC12207973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.